Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (6521)	6/22/1998 5:35:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

On the orphan drug application I believe we will all know at about the same time, since the FDA makes the announcement and its issuance should be part of the public record. Indeed in the announcement of the number of people treated with Neuprex without safety concerns I do not see any concealing of information. In fact I do believe that the DSMB asked XOMA to not discuss the number of deaths. XOMA of course knows how many total deaths occurred in the current trials, but they do not know for sure who has received Neuprex or not. Even so I still agree that XOMA at times leaves us in the dark. Since Ellen gets the credit for the great job, which I think XOMA, does in the area of shareholder relations, then she deserves the blame even if it for not being able to convince her bosses that shareholders have a right to be told as much as possible what is going on. I think some big shot decided we did not need to be told about the last DSMB decision to continue. True, we did not NEED to know since it was an expected event , but it would have been nice to know. I don't want to be the first to know, but I do want XOMA to provide this sort of information to all on its web site. Everyone can make their own decision on its importance.